摘要
目的评价CPT-11(开普拓)联合丝裂霉素(MMC)治疗妇科恶性肿瘤的疗效和毒性。方法采用CPT-11 120mg/m^2 iv4hr和丝裂霉素7mg/m^2 iv,两者均第1和第15天给药,6周一疗程,或CPT-1150～60mg/m^2 iv和丝裂霉素5～6mg/m^2 iv,第1和第8天,3周一疗程。除肿瘤进展外,至少用2疗程。结果 15例中12例可评价疗效,PR部分缓解3例,总有效率25％(3/12),其中6例卵巢和阴道透明细胞癌中3例PR,有效率50％(3/6)。1例粘液癌和5例难治性卵巢上皮癌中1例SD,共33个疗程可评价毒性,主要毒性为骨髓抑制,Ⅲ和Ⅳ度白血球减少占28.1％,Ⅲ～Ⅳ度血小板减少占15.6％,6例病人出现腹泻,Ⅲ～Ⅳ度2例。其余副反应有轻-中度恶心、呕吐、乏力,中度脱发等。结论 CPT-11联合MMC是治疗妇科透明细胞癌和耐药卵巢上皮癌的有效方案、毒性可耐受。
Objective To evaluate the effect and toxicity of CPT- 11 (Irinotocan) plus MMC (mytomycin - C) for advanced gynecologic maligancies. Methods: One regimen is CPT -11 120mg/m2 iv 4hr and MMC 7mg/m2 iv the first and 15th days in a 6 - week cycle.The other one is CPT - 11 50 ~ 60mg/m2 iv and MMC 5 ~ 6mg/m2 iv both on the first and 8th days in a 3 - week cycle.each patient was given at least 2 cycles except those with progression.Results: of the 15 enrolled patients, 12 were evaluable for response.3 patients achieved PR (25%, 3/12) .3 cases of the 6 with ovarian or vaginal clear cell cancer were PR (50% , 3/6) . 1 patients with mucinous cancer and 1 of the 5 refractory epithelial ovarian cancer was SD.A total of 33 cycles were evaluable for toxicity.The main toxicites were: arrest of bone marrow, Neu-tropenia grade Ⅲ and Ⅳ accounting for 28.1 %, thrombocytopenia grade Ⅲ and Ⅳ 15.6%; diarrhea in 6 cases (including 2 cases with diarrhea grade Ⅲ ~ Ⅳ ) .Other side effects included mild or moderate nausea, vomiting, fatigue and moderate alopecia.Conclusion: The regimen of CPT- 11 plus MMC appears to be active in gynecologic clear cell cancer and drug resistant ovarian epithelial cancer with acceptable toxicity.
出处
《医学研究通讯》
2002年第10期50-52,共3页
Bulletin of Medical Research
